Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT07149506

Oral or Topical Catechins for Radiation Dermatitis

Efficacy of Oral or Topical Catechins vs. Placebo as an Adjuvant for the Prevention and Management of Radiation Dermatitis in Oncology Patients: a Randomized Trial

Status
Enrolling By Invitation
Phase
Phase 3
Study type
Interventional
Enrollment
162 (estimated)
Sponsor
CARLOS FRANCISCO SAAVEDRA GARCIA · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Introduction Radiation-induced dermatitis (RID), which includes both acute and chronic forms, affects up to 95% of patients undergoing radiation therapy. Despite its high incidence, there are currently no validated prevention and management recommendations specifically for the mexican population. Catechins, particularly epigallocatechin gallate and epicatechin, are emerging as a promising and readily accessible therapeutic option for radiation damage in skin and other organs, including conditions like esophagitis, intestinal injury, and mucositis. Objective This study aims to evaluate the utility of oral or topical catechins in preventing and managing acute and chronic radiation-induced dermatitis in cancer patients, comparing their effectiveness against standard treatment. Material and Methods This will be a randomized, double-blind, phase III clinical trial with a longitudinal and comparative design. Patients will be allocated into two primary study groups: prevention (n=81) and treatment (n=81). Each group will be further divided into four treatment arms: Epigallocatechin gallate (experimental aerosol) Epicatechin (experimental capsule) Saline control arm (aerosol) Microcrystalline cellulose excipient control arm (capsule) All participants across all groups will receive standard care. Study endpoints will include the assessment of utility, toxicity, quality of life, and cosmesis, using various validated scales and scores. Ethics This study adheres to the principles outlined in the Helsinki Declaration (2024), the Nuremberg Code, and Mexico's General Health Law on health research. Given the wide therapeutic margin of the interventions, the study is classified as minimal risk. Statistical Analysis To evaluate the efficacy of the intervention (specifically, the change in the risk of dermatitis and fibrosis), we will calculate the hazard ratio using Cox regression and compare it with the Log-Rank test. Additionally, both fixed and random effects models will be performed and compared using the likelihood ratio test.

Conditions

Interventions

TypeNameDescription
OTHEREpicatechinA comparison will be made between oral catechin (epicatechin) from two approaches: a preventive approach and a therapeutic approach.
OTHEREpigallocatechin Gallate (EGCG)A comparison will be made between topical catechin (EGCG) from two approaches: a preventive approach and a therapeutic approach.
OTHERMicrocrystalline Cellulose NF (placebo)A comparison will be made between oral placebo (microcrystalline cellulose) from two approaches: a preventive approach and a therapeutic approach.
OTHERSaline (0.9% NaCl)A comparison will be made between topical placebo (0.9% saline solution) from two approaches: a preventive approach and a therapeutic approach.

Timeline

Start date
2025-09-01
Primary completion
2026-10-01
Completion
2027-03-01
First posted
2025-09-02
Last updated
2025-09-08

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT07149506. Inclusion in this directory is not an endorsement.